964,391 Shares in DBV Technologies S.A. $DBVT Purchased by Perceptive Advisors LLC

Perceptive Advisors LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the 1st quarter, HoldingsChannel reports. The institutional investor bought 964,391 shares of the company’s stock, valued at approximately $20,146,000.

A number of other hedge funds have also added to or reduced their stakes in DBVT. Truvestments Capital LLC increased its position in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares during the period. Allworth Financial LP purchased a new stake in shares of DBV Technologies in the fourth quarter worth about $32,000. Royal Bank of Canada bought a new position in shares of DBV Technologies in the fourth quarter valued at approximately $34,000. Persistent Asset Partners Ltd bought a new position in shares of DBV Technologies in the fourth quarter valued at approximately $115,000. Finally, Cetera Investment Advisers grew its stake in DBV Technologies by 93.4% during the first quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock valued at $530,000 after acquiring an additional 12,243 shares in the last quarter. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Trading Down 2.2%

Shares of DBVT opened at $13.50 on Friday. The company has a market cap of $799.34 million, a PE ratio of -3.85 and a beta of -0.95. The stock has a 50-day moving average price of $16.06 and a 200-day moving average price of $19.17. DBV Technologies S.A. has a 12-month low of $8.51 and a 12-month high of $26.18.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.90 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%. As a group, analysts predict that DBV Technologies S.A. will post -2.05 earnings per share for the current year.

Analyst Ratings Changes

DBVT has been the topic of a number of analyst reports. Citizens Jmp upped their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Guggenheim reaffirmed a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a report on Monday, May 4th. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, DBV Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.